Integrated lipid nanoparticle co-delivery solutions for synchronized transport of multiple therapeutic payloads.
Lipid nanoparticles for co-delivery are designed to encapsulate, protect, and transport two or more active components within a coordinated nanocarrier system. Unlike single-payload LNPs, co-delivery formulations must balance different molecular sizes, charge profiles, solubility properties, release kinetics, and intracellular action sites within one stable architecture. This makes formulation design particularly demanding for projects involving mRNA-siRNA combinations, RNA-small molecule systems, protein-nucleic acid delivery, peptide-guided constructs, or multi-drug lipid nanocarriers. BOC Sciences provides specialized LNP co-delivery development services that integrate lipid composition screening, cargo compatibility assessment, microfluidic formulation, encapsulation optimization, physicochemical characterization, and functional evaluation. Our goal is to help drug discovery and formulation teams build robust co-delivery systems that improve payload colocalization, reduce formulation complexity, and support mechanism-driven combination strategies in advanced nanomedicine research.
LNP Structure for Dual Cargo DeliveryWe provide a systematic formulation development platform for complex LNP co-delivery projects, from early feasibility assessment to formulation optimization and performance evaluation. Each project is designed around the physicochemical relationship between the selected cargoes and the lipid carrier architecture.
Successful co-delivery begins with understanding whether multiple payloads can coexist within the same lipid nanoparticle without compromising encapsulation, stability, or functional activity.
We develop LNP systems for simultaneous delivery of multiple nucleic acids, including mRNA-siRNA, mRNA-miRNA mimic, siRNA-siRNA, and RNA guide-related combinations.
For combination strategies requiring gene modulation and pharmacological intervention, we support LNP systems that co-load nucleic acids and hydrophobic or amphiphilic small molecules.
We support co-delivery formulations involving structurally sensitive biomolecules, where protein folding, peptide charge, and nucleic acid complexation must be managed within one nanoparticle system.
Controlled mixing is essential for reproducible LNP co-delivery because different payloads may respond differently to ethanol dilution, pH shift, ionic strength, and residence time.
We apply a multidimensional characterization framework to determine whether the formulation delivers both cargoes as intended rather than simply mixing two separate nanoparticle populations.
Different co-delivery projects require different formulation logic. BOC Sciences designs LNP systems according to cargo pairing, molecular interaction risk, intended cellular process, and required analytical readouts.
| Co-Delivery Format | Typical Project Goals and Design Considerations |
|---|---|
| mRNA + siRNA LNPs | Useful for projects requiring simultaneous protein expression and gene silencing. Formulation development focuses on RNA ratio control, ionizable lipid selection, encapsulation balance, and intracellular release compatibility, especially when the system builds on established lipid nanoparticles for mRNA delivery strategies. |
| siRNA + Small Molecule LNPs | Designed for combination approaches where gene knockdown is paired with modulation of a signaling pathway. Key challenges include hydrophobic drug retention, RNA protection, and differential release behavior; for RNA-centered designs, our experience in lipid nanoparticles for siRNA delivery helps guide charge ratio and encapsulation optimization. |
| mRNA + Small Molecule LNPs | Enables delivery of coding RNA together with a small molecule modulator. Formulation work focuses on avoiding drug precipitation, maintaining mRNA integrity, and confirming that both cargoes remain associated with the same nanoparticle fraction. |
| pDNA + RNA LNPs | Used when large nucleic acid structures and smaller RNA payloads must be co-formulated. Development emphasizes particle architecture, nucleic acid compaction, viscosity control, and protection from nuclease-sensitive conditions, drawing on formulation principles used in lipid nanoparticles for pDNA delivery. |
| Protein + RNA LNPs | Suitable for exploratory systems combining functional proteins with nucleic acids. Important parameters include protein conformation, lipid-protein interaction, encapsulation route, and recovery after formulation, which can be further supported by LNP-based protein delivery development experience. |
| Peptide + Nucleic Acid LNPs | Supports systems where peptides contribute targeting, intracellular trafficking, or biological function. Development may involve peptide positioning on the particle surface or incorporation into the lipid matrix, depending on the design logic used for LNP-based peptide delivery. |
| Dual Small Molecule LNPs | Designed for co-loading hydrophobic, amphiphilic, or ionizable small molecules into lipid domains. Work focuses on solubility windows, drug-drug compatibility, retention, and release differentiation. |
| Targeted Co-Delivery LNPs | Incorporates ligand, peptide, antibody, or organ-biased lipid design to improve cell or tissue interaction. For projects requiring selective cellular interaction, targeted LNP development can be integrated into the co-delivery design. |
Share your cargo types, target ratio, and evaluation goal. Our formulation scientists can help design a practical LNP co-delivery strategy for your research program.
Co-delivery LNP development requires more than simply combining two active ingredients. BOC Sciences uses formulation logic that considers cargo partitioning, lipid architecture, charge balance, and release requirements from the earliest design stage.
Co-delivery LNPs introduce analytical and formulation issues that are rarely visible in single-payload systems. Our development workflow is designed to identify these risks early.
✔ Unbalanced Payload Encapsulation
One cargo may load efficiently while the second remains free in solution. We optimize charge ratio, lipid composition, cargo input ratio, and mixing sequence to improve co-encapsulation balance.
✔ Cargo-Cargo Interference
RNA, peptides, proteins, and small molecules can interact before or during particle assembly. We evaluate precipitation, binding, degradation, and assay interference to redesign the loading strategy.
✔ Particle Heterogeneity
Apparent co-delivery may actually contain two nanoparticle populations. We combine size analysis, fractionation, and payload-specific quantification to verify whether both cargoes are associated with the same LNP fraction.
✔ Differential Release Behavior
Small molecules may diffuse out faster than RNA, while protein payloads may remain surface-bound. We assess retention and release profiles under project-relevant buffer or serum-containing conditions through integrated nanoparticle drug release profiling.
✔ Matrix Interference in Analysis
Lipid excipients can interfere with UV, fluorescence, or chromatography signals. We use orthogonal methods to quantify each payload independently and confirm mass balance through tailored nanoparticle drug loading analysis.
✔ Loss of Functional Activity
Sensitive cargoes may remain physically present but lose activity after formulation. We integrate expression, knockdown, uptake, or protein activity readouts into the development workflow when required.
We review the molecular properties, target ratio, solubility, charge behavior, and stability risks of each cargo. This step defines the most suitable co-loading approach and analytical strategy.
Candidate LNP formulations are prepared by adjusting ionizable lipid composition, helper lipid ratio, PEG-lipid content, buffer conditions, and mixing parameters within a structured lipid nanoparticle formulation workflow.
We characterize particle size, PDI, zeta potential, morphology, encapsulation efficiency, cargo ratio, and stability behavior using project-specific lipid nanoparticle characterization methods.
Lead formulations are refined based on co-loading balance, colloidal stability, release behavior, and optional functional readouts. A structured report summarizes formulation conditions, analytical results, and recommended LNP process optimization paths.
Challenge: A research team needed an LNP system capable of co-delivering a capped mRNA encoding an intracellular reporter protein and an siRNA targeting a pathway-related transcript. Their early formulation showed acceptable particle size, but the siRNA encapsulation efficiency was significantly lower than the mRNA, causing inconsistent knockdown in in vitro cell assays.
Diagnosis: BOC Sciences found that the original aqueous phase contained both RNA species at a fixed mass ratio, but the much shorter siRNA competed poorly during ionizable lipid complexation. Fractionation analysis also suggested that part of the siRNA remained in the external aqueous phase rather than within the LNP-associated fraction.
Solution: We redesigned the co-loading process by screening five mRNA:siRNA input ratios, three N/P ranges, and two buffer pH conditions. A staggered addition strategy was tested in which siRNA was pre-equilibrated with the aqueous phase before mRNA introduction during microfluidic mixing. The optimized formulation maintained a particle size below 120 nm with a narrow PDI, improved siRNA encapsulation, and preserved mRNA expression activity in cell-based evaluation.
Result: The final lead formulation achieved balanced co-encapsulation of both RNA payloads and produced more consistent reporter expression plus target knockdown compared with the client's starting formulation, giving the team a practical platform for further mechanism-of-action studies.
Challenge: A formulation group aimed to co-deliver an siRNA with a hydrophobic kinase-pathway modulator. The initial LNPs showed visible turbidity after storage and a rapid decrease in small molecule content, while siRNA encapsulation remained relatively stable.
Diagnosis: Solubility screening indicated that the hydrophobic compound was exceeding its stable loading window in the lipid phase. HPLC analysis after size-based separation showed that part of the compound crystallized outside the LNP population, leading to overestimation of true co-loaded drug content in bulk assays.
Solution: BOC Sciences evaluated four lipid compositions with adjusted cholesterol and helper lipid ratios, then compared one-step and post-insertion-like loading routes. We also screened reduced small molecule input levels to identify the highest stable co-loading condition rather than the highest theoretical loading. The selected formulation used a moderate drug-to-lipid ratio, maintained siRNA encapsulation, and showed improved small molecule retention during short-term stability testing.
Result: The optimized LNP reduced visible aggregation, improved mass balance between free and LNP-associated small molecule fractions, and provided a more reliable formulation for combination-response evaluation in in vitro models.
Payload-Pair-Specific DesignWe do not apply a generic LNP recipe to every co-delivery project. Each formulation strategy is built around the molecular behavior, target ratio, and functional goal of the selected cargo pair.
Integrated LNP PlatformOur team connects lipid nanoparticles synthesis, formulation development, characterization, encapsulation testing, and functional evaluation within one coordinated workflow.
Orthogonal Analytical CapabilityComplex LNP co-delivery systems require separate quantification of each cargo. We combine fluorescence assays, chromatography, electrophoresis-based methods, and particle fractionation when appropriate.
Experience with Diverse CargoesWe support nucleic acids, peptides, proteins, small molecules, and lipid-associated ligands, enabling flexible design for discovery-stage combination delivery projects.
Targeted Delivery OptionsFor projects requiring cell- or tissue-biased interaction, we can incorporate ligand-functionalized, peptide-functionalized, or composition-driven targeting strategies, including peptide functionalized lipid nanoparticles when peptide-mediated recognition or trafficking is part of the design.
Co-delivery lipid nanoparticles are designed to transport two or more therapeutic or functional cargos within one nanoscale lipid-based formulation. These cargos may include mRNA with an immune-modulating molecule, siRNA with a small-molecule sensitizer, peptide antigens with adjuvant components, or hydrophobic and hydrophilic drugs that need synchronized exposure at the target site. The key value of co-delivery is not simply combining multiple agents, but controlling their ratio, spatial distribution, release behavior, and cellular uptake profile within the same delivery system. For drug development teams, this approach can help explore synergistic mechanisms, reduce formulation complexity, and support more consistent payload presentation in cell-based and animal research models.
Lipid nanoparticles can be engineered to co-encapsulate diverse cargo combinations, but feasibility depends strongly on molecular size, charge, hydrophobicity, structural stability, and the required loading ratio. Common co-delivery formats include nucleic acid-nucleic acid systems such as mRNA/siRNA or siRNA/miRNA, nucleic acid-small molecule systems, protein or peptide-adjuvant systems, and hydrophobic drug combinations integrated into the lipid phase. For charged nucleic acids, ionizable lipid composition and N/P ratio are central design factors. For hydrophobic compounds, lipid solubility and phase compatibility become more important. BOC Sciences can support formulation screening by evaluating lipid composition, cargo compatibility, particle size distribution, encapsulation efficiency, and release characteristics to identify practical co-loading strategies.
Co-delivery LNP development is challenging because each cargo may require different encapsulation conditions, protection mechanisms, and release environments. A lipid composition that efficiently packages siRNA may not be optimal for a hydrophobic small molecule, while a solvent or buffer condition suitable for one component may reduce the stability of another. Researchers also need to manage cargo ratio drift, competitive loading, burst release, aggregation, and analytical interference between payloads. In many projects, the key challenge is maintaining a defined cargo ratio after formulation, purification, storage, and biological dilution. A systematic development strategy should therefore combine formulation design with orthogonal characterization, including particle size, zeta potential, encapsulation efficiency for each cargo, morphology, leakage testing, and functional performance assays.
Co-loaded LNPs require separate and combined analytical evaluation because overall particle quality does not guarantee that both cargos are properly incorporated. Key characterization usually includes particle size and PDI by DLS, zeta potential, morphology by TEM or cryo-TEM, encapsulation efficiency for each payload, drug loading content, cargo ratio confirmation, colloidal stability, serum stability, and release behavior under relevant buffer conditions. For nucleic acids, fluorescence-based accessibility assays, gel electrophoresis, or chromatographic methods may be used. For small molecules, HPLC, UPLC, LC-MS/MS, or fluorescence detection may be selected depending on sensitivity and matrix complexity. BOC Sciences develops fit-for-purpose analytical workflows to distinguish free, surface-associated, and encapsulated cargo fractions in complex LNP systems.
BOC Sciences provides formulation and characterization support for co-delivery lipid nanoparticle projects involving nucleic acids, small molecules, peptides, proteins, and functional excipients. Our work can begin with cargo compatibility assessment, lipid composition selection, and small-scale formulation screening, then move into process parameter optimization such as mixing ratio, flow rate, buffer condition, lipid-to-cargo ratio, and purification strategy. For complex co-loaded systems, we place strong emphasis on analytical reliability, including independent quantification of each cargo, particle stability assessment, and release profile comparison. This helps research teams understand whether poor performance comes from inefficient loading, cargo leakage, aggregation, ratio imbalance, or insufficient cellular uptake, enabling more rational formulation optimization.
